Immune stealth-driven O2 serotype prevalence and potential for therapeutic antibodies against multidrug resistant Klebsiella pneumoniae

Immune stealth-driven O2 serotype prevalence and potential for therapeutic antibodies against multidrug resistant Klebsiella pneumoniae

Therapeutics to combat multidrug-resistant bacteria such as Klebsiella pneumoniae are needed. Here the authors show immune evasion drives lipopolysaccharide O2 serotype expansion in multidrug-resistant isolates, and anti-O-antigen human monoclonal antibodies synergize with antibiotics to protect mic...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Meghan E. Pennini, Anna De Marco, Mark Pelletier, Jessica Bonnell, Romana Cvitkovic, Martina Beltramello, Elisabetta Cameroni, Siro Bianchi, Fabrizia Zatta, Wei Zhao, Xiaodong Xiao, Maria M. Camara, Antonio DiGiandomenico, Elena Semenova, Antonio Lanzavecchia, Paul Warrener, JoAnn Suzich, Qun Wang, Davide Corti, C. Kendall Stover
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2017
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/e53fb32687cc4941aa9b9d884dee44c8
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Therapeutics to combat multidrug-resistant bacteria such as Klebsiella pneumoniae are needed. Here the authors show immune evasion drives lipopolysaccharide O2 serotype expansion in multidrug-resistant isolates, and anti-O-antigen human monoclonal antibodies synergize with antibiotics to protect mice from infection.

Ejemplares similares